Author

Oleksandr Dudchenko

OpenAlex ID: A5114524947

894 Discovery and preclinical development of a half-life-extended TCR-based bispecific T cell engager targeting a novel cancer antigen presented across multiple solid tumor indications

2026 · Dominic Hine, Samhita Rao, et al. · Journal for ImmunoTherapy of Cancer

891 Pre-clinical development of a best-in-class bispecific T cell engager targeting a highly abundant peptide for the treatment of melanoma

2026 · Samantha Drennan, Jong Fu Wong, et al. · Journal for ImmunoTherapy of Cancer

Abstract 3506: Clinic enabling development of a TCR-Ab half life extended T cell engager against a novel solid tumor target

2025 · Sarah Leonard, Hemza Ghadbane, et al. · Cancer Research

1294 Engineering a T cell receptor (TCR) into an antibody drug format provides a novel approach to half-life extended T cell engagers targeting PRAME A2 and PRAME A24

2024 · Hemza Ghadbane, Dominic Hine, et al. · Journal for ImmunoTherapy of Cancer

Works count: 4

Citation count:

H-index:

I10-index: